Roche's Upcoming Data Reveal Puts MS Drug Candidate in Focus

Roche to reveal Phase III data for MS drug fenebrutinib, followed by Q1 sales. Efficacy is strong, but safety data faces scrutiny ahead of regulatory filing.

Investors in Roche Holding AG are set for a significant week, with two closely watched events scheduled back-to-back. The Swiss pharmaceutical giant will unveil new Phase III clinical trial results for its multiple sclerosis candidate, fenebrutinib, on April 22. This will be immediately followed by the release of the company's first-quarter sales figures on April 23.

Dual Mechanism Drug Shows Potent Efficacy

Fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, is being developed for relapsing forms of multiple sclerosis (MS). Data from the pivotal FENhance 1 and FENhance 2 trials have demonstrated strong efficacy. The treatment reduced the annualized relapse rate by 51% and 59%, respectively, compared to the comparator drug teriflunomid over a period of at least 96 weeks. Statistically, this equates to approximately one relapse every 17 years. Secondary study endpoints also confirmed significant reductions in brain lesions.

The therapy’s proposed mechanism of action involves a two-pronged approach. It aims to suppress acute inflammatory flares by inhibiting B-cells, while simultaneously targeting microglia in the brain to counteract the chronic damage believed to be a key driver of long-term disability progression.

Safety Profile Scrutiny Ahead of Regulatory Submission

Despite the promising efficacy signals, safety observations from the trials have raised questions. Researchers reported eight deaths in the fenebrutinib treatment arms across the two studies, compared to one in the control arm. Roche has stated that the causes were varied and that further analyses are ongoing. A critical issue for the market is whether these explanations will satisfy regulatory authorities during the upcoming approval process. The company plans to submit its application alongside data from the separate FENtrepid study. While the full dataset will be publicly presented at the AAN Annual Meeting in 2026, the investor event on April 22 will provide a first look.

Established MS Franchise Gains Reimbursement Momentum

Alongside the pipeline update, Roche’s existing MS business continues to advance. As of April 1, 2025, Ocrevus Zunovo—the subcutaneous formulation of ocrelizumab—has been assigned a permanent J-Code (J2351) in the United States. This designation is a crucial step for broader reimbursement from health insurers and Medicare, facilitating patient access. The subcutaneous version complements the established intravenous infusion therapy, offering people with MS greater flexibility in how they receive treatment.

Roche’s share price experienced notable pressure in late March and early April amid a broader market downturn, trading near a 12-month low at one point. The equity has since shown signs of recovery. The market’s reaction to the dual catalysts of the fenebrutinib data presentation and the Q1 sales report will determine if this upward trend can be sustained.